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Folic	Acid	and	Neural	Tube	Defects	
Rachel	Leah	Feinstein	
	 Neural	tube	defects	(NTD)	are	the	most	common	types	of	birth	defects.	Research	shows	that	
folic	acid	taken	periconceptionally	greatly	reduces	the	risk	of	having	a	NTD	affected	child.	This	paper	will	
explain	the	role	that	folate	plays	in	the	metabolism,	specifically	in	synthesizing	methionine.	It	will	bring	
evidence	to	show	that	methionine	is	crucial	for	normal	neural	tube	development.	In	addition,	it	will	
explore	the	genetic	factor	involved	in	folate	metabolism	and	possible	folate	deficiency.		
	 The	central	nervous	system	in	an	embryo	begins	as	a	flat	region,	which	then	rolls	into	a	tube	
known	as	the	neural	tube.	The	development	of	the	neural	tube	is	completed	28	days	after	the	baby	is	
conceived.	When	the	neural	tube	fails	to	close	completely,	it	is	known	as	a	neural	tube	defect.	The	
nerves	that	are	exposed	to	the	environment	due	to	the	failure	of	the	tube	to	close	may	become	
damaged	causing	the	affected	baby	to	have	a	disability,	specifically	some	measure	of	paralysis.	Neural	
tube	defects	are	one	of	the	most	common	birth	defects,	and	affects	1.3-	2.0	babies	in	every	1,000	live	
births	in	the	United	States.	There	are	two	main	types	of	NTDs,	depending	on	whether	the	cranial	or	
caudal	end	of	the	neural	tube	fails	to	fuse	properly.	The	foremost	cranial	defect	is	known	as	
anaencephaly	which	is	usually	fatal.	The	main	caudal	defect	is	spina	bifida	(Pitkin,	2007).		
	 The	exact	causes	of	NTDs	are	not	clear.	It	is	believed	that	a	combination	of	environmental	
factors,	genetics,	and	nutrition	contribute	to	the	development	of	a	NTD.	However,	as	early	as	the	1970	
scientists	have	suspected	that	folic	acid	taken	by	the	pregnant	mother	helps	prevent	NTDs.	In	the	United	
Kingdom,	R.	W.	Smithells	noticed	that	a	disproportionate	amount	of	babies	affected	with	NTD	were	born	
to	mothers	of	a	lower	socioeconomic	class.	He	hypothesized	that	the	birth	defects	may	have	been	
caused	by	the	mothers’	poor	nutrition.	He	conducted	tests	and	in	1976	reported	that	women	who	had	a	
child	with	an	NTD	had	much	lower	red	cell	folate	and	vitamin	C	levels	than	mothers	who	had	an	
unaffected	child	(Smithells,	Sheppard,	&	Schorah,	1976).	He	then	conducted	a	placebo-controlled	study	
in	which	he	gathered	women	who	had	already	given	birth	to	a	NTD	affected	child.	He	gave	one	group	of	
women	a	multivitamin	and	an	iron	tablet	containing	360	ug	of	folic	acid.	The	group	of	women	who	were	
given	the	vitamin	pill	only	had	a	.5%	occurrence	of	NTD	births,	while	the	control	group	had	a	4%	NTD	
birth	rate	incidence	(Smithells	et	al,	1981).	Smithells	results	were	published,	however	his	experiment	
was	criticized	because	his	subjects	had	not	been	randomized.		
K.	M.	Laurence	in	Whales	also	performed	experiments	with	folic	acid	based	on	Smithells’	works.	
He	performed	a	double	blind	randomized	controlled	trial	of	folate	treatment	prior	to	conception.	Among	
the	group	that	received	the	folate,	there	were	no	NTDs	in	the	group’s	44	births.	However,	in	the	control	
group	there	was	6	NTDs	in	67	births.	Laurence’s	work	was	not	considered	statistically	significant	since	it	
was	performed	on	such	a	small	population	(Mills	et	al.	1996).			
Smithells’	findings	were	eventually	proved	definitively	by	the	Medical	Research	Council	in	1991.	
The	MRC	conducted	a	double-blind	randomized	study	on	women	who	had	a	previous	NTD	pregnancy.	
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Women	received	4	mg	of	folic	acid,	a	multivitamin,	both,	or	iron	and	calcium.	There	was	a	74%	
reduction	of	NTD	births	in	the	group	taking	folic	acid,	but	no	effect	in	the	groups	that	did	not	receive	
folic	acid.	Another	study,	conducted	just	one	year	later	also	helped	to	validate	Smithell’s	works.	Czeizel	
and	Dudas	in	Hungary	enrolled	women	who	had	never	had	an	affected	pregnancy.	They	were	
randomized	and	given	a	multivitamin,	some	with	.8	mg	folic	acid,	and	some	without.	The	group	of	2394	
women	who	were	given	folic	acid	had	no	affected	offspring,	and	the	group	of	2310	women	who	did	not	
receive	folic	acid	had	6	babies	with	NTD	(Mills	et	al.	1996).		
	 Due	to	the	solid	evidence	of	the	protective	role	of	folic	acid,	public	health	officials	recommend	
women	of	childbearing	age	to	take	400	ug	of	folic	acid	at	least	4	weeks	before	conception,	and	through	
the	first	trimester	of	pregnancy.	Folic	acid	is	the	oxidized	and	most	active	form	of	folate.	They	may	do	
this	by	taking	a	folic	acid	supplement.	They	are	also	encouraged	to	eat	folic	acid	enriched	grain	products	
and	large	amounts	of	folate	rich	foods	such	as	green	leafy	vegetables,	or	liver.	The	United	States,	as	well	
as	other	countries,	have	implemented	a	mandatory	folic	acid	food	fortification	and	have	seen	about	a	
50%	reduction	in	the	occurrence	of	NTDs	(Lamers,	Prinz-Langenohl,	Bramswig,	Pietrzik,	2006).			
	 Despite	the	awareness	of	the	role	that	folic	acid	plays	in	preventing	NTDs,	the	exact	mechanism	
used	to	achieve	this	is	not	so	clear	and	is	still	being	studied.	However,	based	on	various	experiments	
scientists	have	come	to	a	basic	understanding	as	to	how	a	folate	deficiency	would	contribute	to	an	NTD	
development.		
	 Folate	is	a	term	to	describe	a	water-	soluble	B-complex	vitamin	and	it	serves	many	important	
roles	in	the	body.	It	is	vital	for	cell	division	and	homeostasis	due	to	the	essential	role	of	folate	
coenzymes	in	nucleic	acid	synthesis,	methionine	regeneration,	and	in	the	shuttling,	oxidation	and	
reduction	of	one	carbon	units	required	for	normal	metabolism	and	regulation.	There	is	an	increase	in	
folate	requirement	in	pregnant	women	to	support	the	rapid	growth	of	the	embryo	and	uteroplacental	
organs.	There	has	been	much	focus	on	the	role	folate	plays	in	methionine	regeneration	in	regard	to	
studies	of	NTDs.	In	this	process	folate	is	reduced	in	the	body	to	dihydrofolate	and	then	to	
tetrahydrofolate.	Tetrahydrofolate	acts	as	an	acceptor	molecule	that	accepts	and	donates	one	carbon	
units	in	metabolic	pathways.		A	one	carbon	unit	is	transferred	from	serine	to	THF	by	serine	
hydroxymethyltransferase	to	form	5,10	methylene	tetrahydrofolate.	This	compound	is	then	reduced	by	
methylene	tetrahydrofolate	reductase	(MTHFR)	to	form	5	methyl	tetrahydrofolate.	The	5	methyl	
tetrahydrofolate	is	acted	upon	by	methionine	synthase	together	with	a	B-12	cofactor	which	facilitates	
the	removal	of	the	N-5	methyl	group	from	the	5	methyl	tetrahydrofolate	and	deposits	it	onto	
homocysteine.	The	homocysteine	with	the	extra	methyl	group	is	known	as	methionine.	A	mother	who	is	
lacking	in	folate	would	not	be	able	to	carry	out	this	metabolic	pathway,	since	5	methyl	tetrahydrofolate	
is	the	only	compound	capable	of	this	one	carbon	transfer	(Bailey,	&	Gregory,	1999).	It	would	therefore	
seem	plausible	to	say	that	mothers	lacking	in	folate,	and	therefore	at	risk	for	an	NTD	baby,	would	have	
elevated	homocysteine	levels	and	low	methionine	levels.	Subsequent	studies	have	indeed	supported	
this	theory.	 		
	 Steegers-	Theunissen	et	al.	(1995)	was	one	of	the	first	to	report	elevated	amniotic	fluid	
homocysteine	in	women	who	were	carrying	an	NTD	fetus.	Since	then	there	have	been	many	reports	that	
40	
	
plasma	or	amniotic	fluid	homocysteine	is	higher	in	NTD	infants	and	their	mothers	than	non-NTD	infants	
and	their	mothers.	One	such	study	was	conducted	by	Mills	in	which	blood	samples	were	collected	during	
pregnancy	from	women	carrying	affected	fetuses,	and	random	women	carrying	healthy	fetuses.	The	
homocysteine	levels	in	the	blood	were	measured,	and	the	mothers	if	NTD	fetuses	had	significantly	
higher	levels.	These	studies	pointed	to	the	relative	inability	of	mothers	with	NTD	babies	to	metabolize	
homocysteine	(Mills	et	al.	1996).		
	 Since	it	has	been	established	that	NTD	mothers	have	higher	levels	of	homocysteine,	research	
turned	to	try	to	establish	if	too	much	homocysteine	is	what	actually	inhibits	the	neural	tube	closure.	In	
order	to	test	this	hypothesis	Greene,	Dunlevy	and	Copps	(2003)	cultured	mouse	embryos	in	the	
presence	of	homocysteine	thiolactone	during	the	periods	of	cranial	neural	tube	closure.	While	the	
homocysteine	thiolactone	did	cause	growth	retardation	and	other	negative	effects,	it	did	not	increase	
the	incidence	of	neural	tube	defects.	Another	study	conducted	by	Afman,	Blom,	Van	Der	Put,	and	Van	
Straaten	(2003)	and	his	colleagues	administered	homocysteine	to	chick	embryos	in	ova.	This	resulted	in	
several	malformations,	but	did	not	increase	the	number	of	NTDs.	These	results	suggest	that	too	much	
homocysteine	is	unlikely	to	be	the	direct	cause	of	NTD.	
	 Since	the	overabundance	of	homocysteine	in	a	mother	of	an	NTD	child	does	not	seem	to	cause	
the	NTD,	perhaps	the	lack	of	methionine	that	should	have	been	made	from	the	homocysteine	plays	a	
role	in	the	development	of	an	NTD.	Methionine	is	an	essential	amino	acid	that	cannot	be	obtained	
sufficiently	through	dietary	intake	and	therefore	must	be	synthesized	by	the	body.	Methionine	formed	
from	homocysteine	is	converted	to	S-	adenosylmethionine,	which	is	a	methyl	donor	for	many	reactions	
including	DNA	methylation	(Friso	et	al.	2002).	This	theory	was	tested	in	a	few	different	ways.	Coelho,	
Weber,	Klein,	Daniels,	and	Thomas	(1989)	conducted	a	study	in	which	he	grew	rat	embryos	in	cow	
serum.	Cow	serum	has	a	much	lower	level	of	methionine	than	rat	serum.	They	supplemented	some	cow	
serum	with	methionine,	and	did	not	supplement	others.	There	was	a	significant	decrease	in	the	
occurrence	of	NTD	in	the	embryos	that	were	grown	in	the	serum	that	was	supplemented	with	
methionine.	Essein	and	Wannberg	(1993)	conducted	a	study	involving	pregnant	mice	with	an	Axd	(axial	
defect)	mutation	which	is	known	to	cause	NTDs.	They	injected	these	pregnant	mice	with	methionine	on	
days	8	and	9	of	the	pregnancy.	At	a	dose	of	180	mg/	kg	body	weight	the	methionine	produced	a	47%	
reduction	of	NTDs.	They	also	conducted	studies	with	mice	with	the	Axd	mutation	in	which	they	
supplemented	the	mice	with	folinic	acid,	but	it	had	no	effect	on	the	incidence	of	NTDs.	This	seems	to	
suggest	that	folate,	or	lack	of	it,	is	an	indirect	cause	of	NTD,	and	methionine	is	the	needed	product	of	
the	folate	for	normal	neural	tube	development.	Perhaps	the	Axd	mutation	codes	for	a	mutation	in	an	
enzyme	that	is	crucial	to	make	methionine,	or	a	vital	product	of	methionine,	but	is	not	involved	with	
folate	at	all.				
	 Shaw,	Velie,	Schaffer	(1997)	conducted	a	study	concerning	the	effect	of	methionine	on	humans.	
His	study	involved	424	mothers	of	NTD	children,	and	440	mothers	of	unaffected	children.	Each	mother	
was	interviewed	in	which	they	answered	a	100	item	food	frequency	questionnaire.	The	data	was	then	
established	into	quartiles	of	average	daily	maternal	dietary	intake	of	methionine	in	the	3	months	before	
conception.	There	was	a	30-	40	%	reduction	in	NTD	affected	pregnancies	among	women	whose	average	
daily	intake	of	methionine	was	above	the	lowest	quartile.	These	observations	were	unrelated	to	the	
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maternal	level	of	folate	intake,	which	supports	the	theory	that	methionine,	or	what	methioine	is	
converted	to,	is	what	is	actually	crucial	for	normal	neural	tube	development.			
	 Assuming	that	methionine	is	vital	for	normal	embryonic	development,	and	the	synthesis	of	
methionine	is	formed	by	homocysteine	and	5	methyl	tetrahydrofolate	interaction,	then	it	is	clear	how	a	
folate	deficiency	would	result	in	a	NTD.	However,	many	studies	since	Smithells	have	reported	that	NTD	
mothers	are	not	necessarily	folate	deficient.	One	such	study	was	conducted	in	Molloy	and	Kirke,	Hillary,	
Weir,	and	Scott	(1985).	They	studied	the	serum	samples	taken	during	pregnancy	from	32	mothers	with	
pregnancies	affected	by	NTD	and	395	randomly	selected	unaffected	pregnant	women.	The	serum	folate	
levels	and	vitamin	B-12	levels	(vitamin	B-12	is	the	coenzyme	that	facilitates	the	removal	of	a	methyl	
group	from	the	5	methyl	tetrahydrofolate	onto	the	homocysteine)	were	measured	and	analyzed.	To	
analyze	the	data	the	information	was	sub-	classified	into	folate	deficient,	possible	deficient,	and	
sufficient	ranges.	The	ranges	were	0-2	ng/ml,	2.01-	2.7	ng/ml,	and	2.71-20	ng/ml	respectively.	
Surprisingly,	only	21.9%	of	the	NTD	group	was	deficient	in	either	folate	or	vitamin	B-12	while	22.8%	of	
the	control	group	samples	were.	43.8%	of	the	NTD	group,	and	35.7%	of	the	control	group	showed	
sufficient	serum	concentrations	of	both	folate	and	vitamin	B-12.	These	results	show	that	a	significant	
percent	of	women	who	had	folate	sufficient	levels	had	a	pregnancy	affected	by	NTD.	This	seems	to	
indicate	that	folate	deficiency	may	not	be	the	sole	or	main	cause	of	neural	tube	defects.	There	may	be	a	
more	subtle	problem	among	women	who	gave	birth	to	NTD	babies	than	simply	not	consuming	enough	
folate	as	part	of	their	diet.	These	results	do	not	contradict	Smithells’	findings,	since	he	reported	that	
NTD	mothers	have	lower	red	cell	folate	levels.	This	study	was	only	able	to	measure	the	serum	folate	
levels,	and	this	difference	seems	to	be	significant.	
	 Red	cell	folate	levels	and	serum	folate	levels	were	further	investigated	in	other	studies.	Once	
such	study	was	conducted	by	Yates	et	al.	(1986)	measured	vitamin	levels	in	twenty	women	less	than	35	
years	of	age	who	had	two	or	more	NTD	pregnancies.	Each	case	was	compared	to	a	control	female	who	
was	matched	for	age,	obstetric	history,	and	social	class.	The	red	cell	folate	levels	were	measured	and	
showed	a	linear	relationship	with	the	number	of	NTD	pregnancies.	However,	there	was	no	significant	
difference	between	the	subjects	and	controls	in	relation	to	serum	folate	levels.	The	diets	of	the	study	
and	control	women	were	ascertained	through	a	questionnaire.	There	was	no	statistically	significant	
difference	between	the	folate	dietary	intakes	of	the	two	groups	of	women.	However,	regression	analysis	
showed	a	difference	between	the	two	groups	in	regard	to	the	relationship	of	red	cell	folate	to	dietary	
folate.	This	study	provides	additional	evidence	that	low	red	cell	folate	is	linked	to	NTD,	but	also	
demonstrates	that	low	red	cell	folate	is	not	necessarily	due	to	a	folate	deficient	diet.	The	difference	
between	the	red	cell	folate	levels	among	women	with	similar	folate	intake	supported	the	increasingly	
popular	idea	that	NTD	may	be	linked	to	a	disorder	in	folate	metabolism,	and	not	exclusively	to	a	folate	
deficient	diet.	
	 More	recently,	in	1992	Mills	et	al.	conducted	a	study	which	measured	the	maternal	serum	folate	
of	89	NTD	pregnancies	and	178	control	pregnancies.	This	study	also	demonstrated	no	relationship	
between	maternal	serum	folate	during	pregnancy	and	the	risk	of	NTDs	(Mills	et	al.	1996).	
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	 There	is	also	a	strong	hereditary	link	for	neural	tube	defects.	The	chance	of	having	a	NTD	child	is	
about	0.15	percent.	However,	once	a	woman	has	a	child	with	a	NTD	the	chance	of	having	a	second	child	
with	NTD	is	increased	to	about	2-5%.	Furthermore,	if	the	women	herself	has	a	NTD	the	chances	of	
having	an	affected	baby	increases.	This	supports	the	idea	that	there	may	be	a	genetic	mutation	that	
predisposes	someone	for	NTD	among	those	who	are	affected	by	it	(Genetics	and	Neural	Tube	Defects,	
2005).	
	 Due	to	the	evidence	provided	by	studies	such	as	the	ones	mentioned	above,	there	has	been	
much	speculation	that	there	is	possibly	a	genetic	defect	that	affects	the	metabolism	of	folate.	To	prove	
this	hypothesis	researchers	have	identified	several	common	polymorphisms	of	genes	that	code	for	
folate	metabolizing	enzymes,	including	the	677C	/	677T	and	the	1298A/	1298C	alleles	of	5,	10	
methylenetetrahydrofolate	reductase	(MTHFR).	These	polymorphisms	are	common,	and	their	frequency	
varies	by	race	and	ethnicity.	A	recent	study	by	Yang	et	al.	(2008)	tried	to	determine	the	role	that	these	
different	alleles	play	in	the	metabolism	of	folate	and	homocysteine	levels.		
	 Data	for	this	study	was	taken	from	the	third	National	Health	and	Nutrition	Examination	Survey	
(NHANES	III).	The	NHANES	III	endeavored	to	obtain	a	nationally	representative	sample	of	the	civilian	
United	States	population.	Each	survey	participant	was	given	an	interview,	a	physical	examination,	and	
gave	a	sample	of	their	blood.	The	researchers	genotyped	selected	polymorphisms	of	folate	metabolizing	
enzymes	in	DNA	samples	(obtained	from	the	blood	specimen)	for	7159	individuals.	They	also	measured	
the	serum	folate	levels	and	homocysteine	levels	in	each	blood	sample.	Based	on	the	interviews	of	the	
participants	their	average	daily	intake	of	folate	was	determined.	The	effects	of	MTHFR	677C/677T	
genotype	and	the	MTHFR	1298A/1298C	genotype	on	the	inverse	relationship	between	folate	intake	and	
serum	homocysteine	concentrations	were	then	examined.		
	 The	researchers	observed	significant	differences	in	the	serum	folate	and	homocysteine	
concentrations	for	individuals	with	the	MTHFR	677	TT	genotype.	The	adjusted	geometric	mean	of	serum	
folate	concentration	was	24.83	%	lower	if	they	had	the	TT	genotype	that	if	they	had	the	CC	genotype.	
The	adjusted	geometric	mean	of	serum	total	homocysteine	concentration	was	29.06%	higher	if	they	had	
the	TT	genotype	than	if	they	had	the	CC	genotype.	The	other	polymorphism,	1298A/1298C,	was	not	
significantly	associated	with	serum	folate	or	homocysteine	concentrations.		
	 Folic	acid	consumption	also	played	an	important	part	in	determining	serum	folate	levels.	Those	
with	the	677	TT	genotype	that	took	400	ug	of	folic	acid	per	day	had	higher	serum	folate	concentrations	
than	those	with	the	MTHFR	677	CC	who	did	not	take	folic	acid	supplements.	As	the	folic	acid	
consumption	increased,	the	difference	between	the	levels	of	serum	folate	of	the	TT	and	CC	genotypes	
decreased	significantly.	The	difference	actually	became	non	significant	among	the	group	who	took	
400ug	or	more	of	folic	acid	per	day.	However,	homocysteine	levels	among	the	MTHFR	677TT	only	
decreased	by	11-14%	with	the	supplemental	folic	acid.			
		 These	results	seem	to	indicate	that	having	677	TT	alleles	on	the	gene	that	codes	for	MTHFR	
results	in	some	sort	of	defect	on	the	enzyme	which	causes	lower	folate	levels	than	in	someone	who	has	
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the	same	folate	dietary	intake	but	has	the	677	CC	alleles.	However,	consuming	a	lot	of	folic	acid,	
specifically	400	ug	per	day,	can	overcome	the	problem	and	bring	the	serum	folate	to	sufficient	levels.		
	 The	exact	explanation	for	what	the	polymorphism	codes	for,	and	how	the	folate	is	able	to	
overcome	the	defect	can	be	explained.	The	677T	polymorphism	occurs	in	exon	4	of	the	genetic	code	and	
results	in	a	valine	substitution	of	alanine	at	codon	222.	This	valine	lies	on	the	binding	site	for	the	MTHFR	
enzyme’s	cofactor	flavin	adenine	dinucleotide	(FAD).	This	affects	the	binding	of	the	FAD	to	the	enzyme,	
making	the	binding	site	exposed	instead	of	imbedded	in	a	barrel-like	structure.	The	exposure	results	in	a	
weakened,	thermolabile	MTHFR/FAD	complex	and	the	MTHFR	677TT	enzyme	has	been	shown	to	
dissociate	with	the	FAD	cofactor	more	readily	than	the	MTHFR	677CC	enzyme.	This	results	in	decreased	
enzymatic	activity.	The	MTHFR	enzymes	with	the	677TT	genotype	have	a	30%	in	vitro	MTHFR	enzyme	
activity	as	compared	to	the	MTHFR	677CC	enzymes.		However,	an	abundance	of	5-	
methyltetrahydrofolate	substrates	have	been	shown	to	strengthen	the	complex	and	protect	the	MTHFR	
from	losing	the	FAD	cofactor.	This	explains	how	consuming	an	abundance	of	folic	acid	overcomes	a	
natural	genetic	deficiency	(Robien,	&	Ulrich,	2003).		
	 The	results	of	the	study	by	Yang		et	al.	explains	the	findings	in	the	studies	which	show	that	
people	of	similar	folate	intake	may	have	different	red	cell	folate	levels.		However,	in	the	those	studies,	
the	women	who	had	given	birth	to	NTD	children	did	have	sufficient	serum	folate	levels,	while	in	the	
study	by	Yang	the	MTHFR	reduced	activity	was	specifically	reflected	in	low	serum	levels.	It	is	possible	
that	this	can	be	explained	simply	by	the	different	states	of	the	subjects	of	the	studies.	The	studies	that	
showed	similar	serum	levels	were	conducted	on	pregnant	women.	It	has	already	been	established	that	
pregnant	women	are	in	high	need	of	folate.	The	plasma	is	the	provider	of	folate	during	pregnancy	and	
therefore	the	body	does	al	it	can	to	ensure	sufficient	serum	folate.	When	the	maternal	serum	folate	
reaches	deficient	levels,	folate	is	taken	from	the	red	cells	that	serve	as	folate	storage	tissue	(Lamers,	
Prinz-Langenhol,	Bramswig,	&	Pietrzik,	2006).	That	would	explain	the	consistent	findings	of	low	red	cell	
folate	levels,	but	sufficient	serum	folate	levels	of	the	NTD	mothers.	However,	the	study	of	
polymorphisms	was	conducted	on	a	representational	population	of	United	States	residents,	and	
therefore	presumably	only	has	a	small	percent	of	pregnant	women.	Since	folate	is	not	as	desperately	
needed	among	non-pregnant	people,	the	body	has	no	urgent	need	to	bring	up	the	serum	folate	levels,	
and	therefore	they	remain	deficient.		
	 If	the	677TT	MTHFR	polymorphism	is	actually	what	leads	to	low	serum	folate	and	high	total	
homocysteine	levels,	perhaps	it	would	be	more	efficient	to	simply	supplement	the	body	with	what	the	
MTHFR	should	be	synthesizing	rather	than	with	folic	acid	which	stabilizes	the	enzyme.	This	speculation	
was	proven	true	in	a	study	by	Lamers	et	al.	(2006).	The	study	involved	144	women	aged	19-33	who	were	
not	pregnant	or	lactating.	The	study	was	a	24	week	double-blind	placebo-controlled	trial.		The	women	
received	either	400ug	of	folic	acid,	416	ug	[6S]	5	methyltetrahydrofolate,	208	ug	[6S]	5	
methyltetrahydrofolate,	or	a	placebo	daily.	Blood	samples	were	collected	every	4	weeks	of	the	study.	At	
baseline,	the	4	groups	did	not	differ	significantly	with	respect	to	red	cell	and	serum	folate	concentration.	
No	change	in	dietary	intake	was	observed	throughout	the	study	period.	Although	all	3	groups	receiving	
supplements	showed	significant	red	cell	and	serum	folate	increases,	the	increase	in	red	cell	folate	and	
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serum	folate	was	significantly	greater	in	the	group	receiving	416	ug	[6S]	5	methyltetrahydrofolate	than	
the	other	2	groups.	The	group	that	received	400	ug	of	folic	acid	had	the	second	highest	increse.			
	 This	study	proves	that	supplemental	[6S]	5	methyltetrahydrofolate	at	approximately	the	same	
dosage	as	supplemental	folic	acid	is	more	efficient	than	folic	acid	at	raising	folate	levels.		This	supports	
the	idea	that	the	lag	in	the	folate	metabolism	present	in	some	people	occurs	at	the	MTHFR	enzyme	
which	is	supposed	to	synthesize	5		methyltetrahydrofolate.	Therefore	providing	the	body	with	the	
product	of	the	enzyme	overcomes	the	defect	more	efficiently	than	trying	to	stabilize	the	enzyme	with	
additional	folic	acid.		
	 The	role	that	folic	acid	plays	in	the	prevention	of	the	occurrence	of	a	NTD	is	well	documented	
and	proven.	Folic	acid	aids	in	the	deposition	of	a	methyl	group	on	homocysteine,	thereby	creating	
methionine.	Methionine	is	then	converted	to	other	substances,	such	as	S-	adenosylmethionine,	which	is	
essential	for	normal	embryonic	development.	Pregnant	women	who	are	folate	deficient	may	therefore	
not	have	sufficient	methionine	levels	to	support	a	growing	embryo.	This	could	lead	to	birth	defects,	such	
as	the	failure	of	the	neural	tube	to	close	properly.	Pregnant	women	may	be	folate	deficient	due	to	a	
poor	diet.	However,	even	women	who	do	have	a	folate	sufficient	diet	may	have	low	red	cell	folate	
serum	levels	if	they	have	the	677TT	MTHFR	polymorphism.	This	genetic	defect	can	be	overcome	by	
consuming	an	abundance	of	folic	acid,	beyond	what	is	normally	considered	sufficient.	Today	there	is	
much	effort	expended	on	educating	the	public	about	the	beneficial	role	of	folic	acid,	and	encouraging	
women	of	child	bearing	age	to	take	folic	acid	supplements.		
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